| Names | |
|---|---|
| Preferred IUPAC name 5-[3-(1-Methylcyclopropyl)propyl]-2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-trione | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C14H16N2O4 | |
| Molar mass | 276.292 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials. [1]